Unterstützung von NCI - 500 Beiträge pro Seite
eröffnet am 08.10.09 15:50:52 von
neuester Beitrag 08.10.09 15:55:19 von
neuester Beitrag 08.10.09 15:55:19 von
Beiträge: 2
ID: 1.153.536
ID: 1.153.536
Aufrufe heute: 0
Gesamt: 405
Gesamt: 405
Aktive User: 0
ISIN: US40171F5017 · Symbol: GTHP
0,0932
USD
-6,76 %
-0,0068 USD
Letzter Kurs 25.04.24 Nasdaq OTC
Neuigkeiten
20.02.24 · Business Wire (engl.)  |
20.11.23 · Business Wire (engl.) |
01.05.23 · Business Wire (engl.) |
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 3,2800 | +60,78 | |
| 1,9000 | +59,66 | |
| 4,7450 | +35,57 | |
| 6,4900 | +29,80 | |
| 0,5250 | +19,08 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,7000 | -13,71 | |
| 3,0400 | -19,95 | |
| 1,9500 | -25,14 | |
| 1,6052 | -30,21 | |
| 0,5121 | -30,80 |
Feedback
nicht schlecht für so einen kleinen wert
mit derart geringer MK:
Oct 08, 2009 GTHP - Guided Therapeutics, a US-based medical technology company, has received a $2.5 million matching grant from the National Cancer Institute to bring to market and expand the array features for its LightTouch non-invasive cervical cancer detection technology.
The award provides resources to complete the regulatory process and begin manufacturing ramp up for the device and single-patient-use disposable.
Including the new award, the company has been awarded approximately $6 million in six consecutive grants from the National Cancer Institute (NCI) to develop the new, pain-free test for detecting cervical disease.
According to Guided Therapeutics, the GT LightTouch technology systematically and rapidly scans the cervix to identify cancer and pre-cancer painlessly and non-invasively, by analyzing the wavelengths of light reflected from cervical tissue.
The technology distinguishes between normal and diseased tissue, by detecting biochemical and morphological changes at the cellular level. Unlike Pap or HPV tests, the LightTouch test does not require a tissue sample or laboratory analysis, and is designed to provide results immediately. The technology is designed as a device employing a single-use disposable patient interface, the company added.
Mark Faupel, president and CEO of Guided Therapeutics, said: "This grant provides significant non-dilutive resources for us to begin manufacturing LightTouch devices and disposables for an international launch, as we simultaneously complete the FDA pre-market approval application process."
mit derart geringer MK:
Oct 08, 2009 GTHP - Guided Therapeutics, a US-based medical technology company, has received a $2.5 million matching grant from the National Cancer Institute to bring to market and expand the array features for its LightTouch non-invasive cervical cancer detection technology.
The award provides resources to complete the regulatory process and begin manufacturing ramp up for the device and single-patient-use disposable.
Including the new award, the company has been awarded approximately $6 million in six consecutive grants from the National Cancer Institute (NCI) to develop the new, pain-free test for detecting cervical disease.
According to Guided Therapeutics, the GT LightTouch technology systematically and rapidly scans the cervix to identify cancer and pre-cancer painlessly and non-invasively, by analyzing the wavelengths of light reflected from cervical tissue.
The technology distinguishes between normal and diseased tissue, by detecting biochemical and morphological changes at the cellular level. Unlike Pap or HPV tests, the LightTouch test does not require a tissue sample or laboratory analysis, and is designed to provide results immediately. The technology is designed as a device employing a single-use disposable patient interface, the company added.
Mark Faupel, president and CEO of Guided Therapeutics, said: "This grant provides significant non-dilutive resources for us to begin manufacturing LightTouch devices and disposables for an international launch, as we simultaneously complete the FDA pre-market approval application process."
ein ähnlicher wert hatte in den letzten wochen - IMGG-
schon eine sehr gute performance...
vorsicht: wir befinden uns beim OTC - handel in USA!!
dieser wert auch bereits gut gelaufen in den letzten tagen...aber anzahl der aktien
im vergleich zu IMGG noch sehr gering...
kennt jemand diesen wert?
danke für meinungsaustausch
gustl
schon eine sehr gute performance...
vorsicht: wir befinden uns beim OTC - handel in USA!!
dieser wert auch bereits gut gelaufen in den letzten tagen...aber anzahl der aktien
im vergleich zu IMGG noch sehr gering...
kennt jemand diesen wert?
danke für meinungsaustausch
gustl
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Investoren beobachten auch:
| Wertpapier | Perf. % |
|---|---|
| +0,04 | |
| -4,06 | |
| -0,64 | |
| -0,98 | |
| +0,26 | |
| 0,00 | |
| -0,30 | |
| -0,10 | |
| -0,10 | |
| -0,33 |
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 240 | ||
| 107 | ||
| 82 | ||
| 78 | ||
| 75 | ||
| 53 | ||
| 41 | ||
| 38 | ||
| 36 | ||
| 34 |
